<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001296549</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>6</amendmentNo>
	      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001737287</issuerCik>        <issuerName>Allogene Therapeutics, Inc.</issuerName>        <issuerCusip>019770106</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>210 East Grand Avenue</com:street1>
                    <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	           <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
						      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Arie Belldegrun, M.D.</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>3771157.00</soleVotingPower>
                          <sharedVotingPower>8772287.00</sharedVotingPower>
                          <soleDispositivePower>3771157.00</soleDispositivePower>
                         <sharedDispositivePower>8772287.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>12543444.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.7</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Bellco Legacy LLC</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>539867.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>539867.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>539867.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Bellco Legacy IV LLC</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4710120.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4710120.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4710120.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.1</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Vida Ventures LLC</reportingPersonName>



		 <citizenshipOrOrganization>NV</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1798163.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1798163.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1798163.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.8</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Vida Ventures III, L.P. </reportingPersonName>



		 <citizenshipOrOrganization>NV</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1720172.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1720172.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1720172.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.8</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>



    <reportingPersonName>Vida Ventures III-A, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>NV</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3965.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3965.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3965.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Allogene Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>210 East Grand Avenue, South San Francisco, CA, 94080.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>Arie Belldegrun
Bellco Legacy  LLC
Bellco Legacy IV LLC
Vida Ventures LLC
Vida Ventures III, L.P.
Vida Ventures III-A, L.P.
</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Bellco Legacy  LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Vida Ventures LLC: 40 Broad Street, #201, Boston, MA  02109
Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA  02109
Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA  02109
</principalBusinessOfficeOrResidenceAddress>        <citizenship>Arie Belldegrun: United States and Israel
Bellco Legacy  LLC: Delaware
Bellco Legacy IV LLC: Delaware
Vida Ventures LLC: Nevada
Vida Ventures III, L.P.: Nevada
Vida Ventures III-A, L.P.: Nevada
</citizenship>      </item2>




    <item4>
    <amountBeneficiallyOwned>Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Row 9 of Dr. Belldegrun's cover page includes 3,180,554 shares of common stock issuable within 60 days of March 31, 2025 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director.  Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.</amountBeneficiallyOwned>    <classPercent>Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on  217,264,738  shares of common stock outstanding as of March 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 13, 2025.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                    <notApplicableFlag>Y</notApplicableFlag>

      </item10>
    </items>

		<exhibitInfo>Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Arie Belldegrun, M.D.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>Arie Belldegrun, M.D.</title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Bellco Legacy LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>By Arie Belldegrun, M.D., Manager</title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Bellco Legacy IV LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>By Arie Belldegrun, M.D., Manager</title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Vida Ventures LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director, </title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Vida Ventures III, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director, </title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Vida Ventures III-A, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Arie Belldegrun</signature>
        <title>By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director, </title>
        <date>05/09/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
